Evidence verdict: NAD+ biology is central to cellular energy metabolism and intersects with sirtuins, DNA repair and stress responses. Human studies show that several NAD-related strategies can alter metabolites or intracellular NAD availability, and a small 2026 randomized Phase 0/1b study reported a short-term rise in whole-blood intracellular…
A careful comparison of CoQ10 and omega-3 cardiovascular evidence, including heart-failure trials, prescription formulations, safety and the limits of longevity claims.
Evidence verdict: NR currently has the broader human trial history, while NMN has a growing short-term randomized evidence base and appears generally well tolerated at studied doses. A 2026 head-to-head biomarker study found comparable circulating NAD increases after 14 days of NMN and NR, but neither has demonstrated…
Evidence verdict: The best longevity supplement in 2026 is not a universal stack. A defensible ranking weighs human randomized evidence, meaningful aging-relevant outcomes, replication and safety. Creatine has comparatively strong evidence for selected muscle outcomes in older adults; omega-3 has substantial cardiovascular research but an atrial-fibrillation trade-off; many…
Evidence verdict: Among widely marketed longevity supplements, creatine has one of the stronger human evidence bases for aging-relevant function. Meta-analyses support modest additional gains in lean mass and some strength outcomes when creatine is paired with resistance training in older adults. Cognitive evidence is promising but inconsistent, and…
Evidence verdict: Magnesium is essential for normal physiology, and inadequate status can matter clinically, particularly in older adults and people with gastrointestinal disease, diabetes, alcohol dependence, medication-related losses or impaired intake. Observational studies connect lower magnesium status or intake with frailty, DNA-damage markers and mortality in selected populations.…
Evidence verdict: Omega-3 fatty acids have substantial human evidence for cardiovascular and triglyceride-related outcomes, and higher circulating omega-3 status is often associated with lower mortality in observational cohorts. But supplementation has not been shown to extend human lifespan. The 2025 DO-HEALTH analysis found small favorable changes in several…
Evidence verdict: Sulforaphane reliably engages stress-response biology, especially KEAP1-NRF2 signaling, and has been tested in many human trials across disease areas. That makes it more than a purely preclinical molecule, but no trial has shown that sulforaphane extends human lifespan or broadly slows aging. A 2026 older-adult study…
Evidence verdict: Apigenin is scientifically interesting because CD38 is a plausible contributor to age-associated NAD decline and apigenin can inhibit CD38 in experimental models. There is no human evidence that apigenin slows aging or extends lifespan. Human studies mainly describe absorption, metabolism and apigenin-containing foods or extracts in…
Evidence verdict: Quercetin is not established as a stand-alone human senolytic or longevity therapy. The strongest human senolytic evidence involving it comes from small studies of dasatinib plus quercetin (D+Q), in which the prescription drug dasatinib is an essential part of the intervention. Quercetin-alone studies of blood pressure…